Acquired hemolytic anemia

Global Autoimmune Disease Diagnostic Market to 2025 by Disease, Tests Type, Regions - ResearchAndMarkets.com

Retrieved on: 
Friday, September 6, 2019
Health, Other Health, Medicine, Autoimmune diseases, Health, Actuarial science, Disease, Medical terminology, Autoimmunity, Acquired hemolytic anemia, Hycor Biomedical

The Global Autoimmune Disease Diagnostic Market is expected to surpass US$ 18 Billion by the year-end of 2025.

Key Points: 
  • The Global Autoimmune Disease Diagnostic Market is expected to surpass US$ 18 Billion by the year-end of 2025.
  • Rising technological advancement in diagnostic, increasing patient awareness towards early diagnostic of disease, increasing government healthcare expenditure, increasing per capita expenditure on health, favorable government policies, industry positive initiative towards autoimmune disease and rising research & development on autoimmune will further propel the market of autoimmune disease diagnostic market in the future course of time.
  • In this report, we have categorized the autoimmune disease diagnostics market on the basis of disease into two parts; Systemic autoimmune disease diagnostics and Localized autoimmune disease diagnostics.
  • In this report, we have categorized the autoimmune disease diagnostic market by test type into seven parts along with comprehensive assessment and factor that will boost the diagnostic test market.

Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Retrieved on: 
Friday, September 6, 2019
Professional services, Health, Finance, Pharmaceutical, Biotechnology, Acquired hemolytic anemia, Psychiatric diagnosis, Compulsive behavior, Thrombotic microangiopathy, Medicine, Medical specialties, Organ systems

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next week.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next week.
  • The presentation is scheduled for Tuesday, September 10, 2019 at 10:00 a.m. EDT.
  • The live and archived webcasts can be accessed on the investor relations section of the companys website at www.omeros.com under Events.
  • Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; cognitive impairment; and addictive and compulsive disorders.

Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Tuesday, September 3, 2019
Programming languages, Computer languages, Acquired hemolytic anemia, Paroxysmal nocturnal hemoglobinuria, PNH, APL, Paroxysmal attack, Clinical trial

(NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-nave patients with paroxysmal nocturnal hemoglobinuria (PNH).

Key Points: 
  • (NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-nave patients with paroxysmal nocturnal hemoglobinuria (PNH).
  • PRINCE is the second Phase 3 study that Apellis has initiated to investigate the potential of APL-2 to treat PNH.
  • At Apellis, we believe there is a significant opportunity for APL-2 to be a transformative therapy that could benefit people living with PNH.
  • The PRINCE study is a Phase 3, randomized, multicenter, open-label, controlled study that aims to enroll 54 treatment-nave adult patients with PNH.

Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Retrieved on: 
Wednesday, August 28, 2019
General Health, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Clinical medicine, Blood disorders, Acquired hemolytic anemia, Eculizumab, Immunosuppressants, Escherichia coli, Hemolytic-uremic syndrome, Hus, Aquaporin 4, Alexion Pharmaceuticals, NMOSD, SOLIRIS, Alexion

In the U.S., SOLIRIS is approved for the treatment of adults with NMOSD who are anti-AQP4 antibody positive.

Key Points: 
  • In the U.S., SOLIRIS is approved for the treatment of adults with NMOSD who are anti-AQP4 antibody positive.
  • SOLIRIS received Orphan Drug Designation (ODD) for the treatment of NMOSD in the U.S., EU and Japan.
  • The disease primarily affects women, often in the prime of their lives, with an average age of onset of 39 years.
  • SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS).

Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

Retrieved on: 
Thursday, August 1, 2019
Anemias, Medical specialties, Medicine, Acquired hemolytic anemia, Autoimmune diseases, Hematology, Antibodies, Hematopathology, Autoimmune hemolytic anemia, Hemolysis, Autoantibody, Autoimmunity

The FDA has also granted Fast Track Designation for nipocalimab in wAIHA.

Key Points: 
  • The FDA has also granted Fast Track Designation for nipocalimab in wAIHA.
  • wAIHA is a rare autoimmune disease with high unmet medical need and no labelled treatments.
  • This study initiation is an important milestone for Momenta, marking the start of our third clinical study of nipocalimab in auto and alloimmune diseases.
  • wAIHA is a rare autoimmune hemolytic anemia characterized by the destruction of red blood cells due to the presence of pathogenic IgG autoantibodies.

Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Friday, August 9, 2019
Public relations, Investor relations, Communications, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Acquired hemolytic anemia, Psychiatric diagnosis, Compulsive behavior, Wedbush Securities, Thrombotic microangiopathy, Medicine, Medical specialties, Organ systems

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week.
  • The presentation is scheduled for Wednesday, August 14, 2019 at 2:30 p.m. EDT.
  • The live and archived webcasts can be accessed on the investors relations section of the companys website at www.omeros.com under Events.
  • Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; cognitive impairment; and addictive and compulsive disorders.

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Tuesday, June 18, 2019
Health, Cardiology, Clinical trials, Pharmaceutical, Other Health, Bacteria, Medicine, Medical specialties, Blood disorders, Atypical hemolytic uremic syndrome, Syndromes, Acquired hemolytic anemia, PNH, Paroxysmal nocturnal hemoglobinuria, Paroxysmal attack, Hemoglobinuria, Neisseria meningitidis

The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective .

Key Points: 
  • The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective .
  • ULTOMIRIS is also currently being evaluated in a Phase 3 clinical study in children and adolescents with aHUS, administered intravenously every eight weeks.
  • ULTOMIRIS is used to treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH).
  • If ones doctor decided that urgent treatment with ULTOMIRIS is needed, meningococcal vaccination should be administered as soon as possible.

Hemolytic Uremic Syndrome Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stage, Drug Mechanism Class, Company - ResearchAndMarkets.com

Retrieved on: 
Friday, June 14, 2019
Health, Clinical trials, Pharmaceutical, Health, Medicine, Medical specialties, Acquired hemolytic anemia, Blood disorders, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Hemolytic-uremic syndrome, Hamburger disease

The "Global Hemolytic Uremic Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hemolytic Uremic Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Hemolytic Uremic Syndrome Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Hemolytic Uremic Syndrome market.
  • It covers emerging therapies for Hemolytic Uremic Syndrome in active clinical development stages including early and late stage clinical trials.
  • The report provides Hemolytic Uremic Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)

Retrieved on: 
Thursday, June 13, 2019
Medical specialties, Autoimmune diseases, Medicine, Acquired hemolytic anemia, Hematopathology, Branches of biology, Fostamatinib, Organophosphates, Autoimmune hemolytic anemia, AIHA, Warm antibody autoimmune hemolytic anemia, Hemolytic anemia

SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019.

Key Points: 
  • SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019.
  • Additionally, Rigel will highlight data from its open-label extension period of the SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA).
  • As a result, there remains a significant medical need for additional treatment options for patients with ITP.
  • To date, there are no disease-targeted therapies approved for AIHA, despite the unmet medical need that exists for these patients.

Omeros to Present at the UBS Global Healthcare Conference

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Pharmaceutical, Acquired hemolytic anemia, Psychiatric diagnosis, Compulsive behavior, Thrombotic microangiopathy, Organ systems, Medicine, Branches of biology

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week.
  • The presentation is scheduled for Wednesday, May 22, 2019 at 8:00 a.m. EDT.
  • The live and archived webcasts can be accessed on the investor relations page of companys website at www.omeros.com .
  • Omeroshas multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, cognitive impairment and addictive and compulsive disorders.